Diabetes mellitus is a multifactorial disease caused by a complex interaction of environmental and genetic factors. Some diabetes mellitus cases, however, are caused by a limited number of mutant genes. Chromosome 13q deletion syndrome, an extremely rare genetic disorder, is caused by structural and functional monosomy of the 13q chromosomal region. We report the case of a 38-year-old Japanese man with Chr13q deletion (a mosaic pattern with heterozygous ring Chr13q) who developed diabetes mellitus. Early-onset diabetes mellitus developed in this patient because of insulin resistance and a lack of adequate insulin secretion. Microarray analysis identified a 4.8-Mb deletion of distal Chr13q, leading to a copy number loss of 40 genes. Among those genes, the insulin receptor substrate 2 gene (IRS2) was the most likely causative candidate for the development of diabetes mellitus in this patient, based on the model of IRS2 knockout mice, which have abnormal glucose and insulin homeostasis closely resembling the human diabetes phenotype. These data provide important information regarding the contribution of a microdeletion of Chr13q, including in IRS2, to the pathogenesis of diabetes mellitus in humans.
Case Description
The patient is a 38-year-old Japanese man. He was born after an uneventful 40-week gestation with a birth weight of 2,000 g (less than the third percentile relative to the Japanese population), length of 46.5 cm (10th to 25th percentile), chest circumference of 28.5 cm (less than the third percentile), and head circumference of 28.0 cm (less than the third percentile). The patient's mother, a 29-year-old woman, and her 30-year-old husband were healthy, nonconsanguineous, and had no family history of genetic disorders or congenital malformations. The patient had normal tonus and no feeding difficulties, but all developmental milestones, such as motor skills, language, and cognitive development, were delayed. At more advanced ages, growth retardation and developmental disability became apparent ( Fig. 1A  and 1B) . At the age of 6 years, he was diagnosed with ring Chr13 syndrome. Electroencephalography and brain computed tomography indicated no brain abnormalities. The karyotypes of his parents and younger brother were normal. He attended special classes for handicapped children after elementary school. After that, he had no severe medical illness until age 20 years.
At the age of 21 years, glycosuria was noted in a medical checkup. He was not obese, height was 158.0 cm, weight was 54.0 kg, and body mass index was 21.6 (measured as weight in kilograms divided by height in meters squared). Soon after this medical checkup, he received a diagnosis of diabetes mellitus. His fasting glucose and insulin levels were 127 mg/dL and Microarray-based comparative genomic hybridization (aCGH) analysis in Chr13. The aCGH analysis was performed using the Agilent Oligo Microarray Kits 60K (Agilent Technologies, Santa Clara, CA) as described previously [10] . [8] are shown. The differences in the hemizygous loss region between our patient and those families include IRS2, COL4A1, COL4A2, RAB20, CARKD, and CARS2. FISH, fluorescence in situ hybridization. 16 mU/mL, respectively, and homeostasis model assessment of insulin resistance was 5.0 (reference value, ,2.0). His HbA1c was 7.1%. Subsequently, at age 25 years, he was treated with per os medications (gliclazide 120 mg/d and metformin 750 mg/d). At age 26 years, he was admitted to our hospital and was changed to insulin therapy because of poor glucose control (HbA1c, 10.9%). After the hospitalization, he was diagnosed with having a prolonged prothrombin time and with Wolff-Parkinson-White (WPW) syndrome. At 38 years old, the patient is not obese, height is 158.6 cm, weight is 57.7 kg, and body mass index is 22.9. He has no diabetic complications and no acanthosis nigricans. Anti-islet autoantibodies (specifically, GAD antibody and IA-2 antibody) were negative. Serum C-peptide levels at fasting and after injection of glucagon were 1.05 ng/mL and 1.95 ng/mL, respectively. The insulinogenic index was 0.1. The K index of the insulin tolerance test (using regular insulin, 0.1 U/kg body weight), an indicator of insulin resistance, was 1.70 (reference value, 5.65% 6 0.35%/min) [3] , demonstrating severe insulin resistance with insufficient compensation by insulin secretion. Computed tomography of the thorax and abdomen demonstrated no abnormalities.
The patient received insulin therapy (32 units daily of rapid-acting insulin, namely, insulin aspart; and 14 units daily of long-acting insulin, namely, insulin degludec). After carrying out genome-wide microarray analysis, his medication was changed. A thiazolidine derivative (30 mg/d), which has been reported to augment IRS-2 expression [4] , was added to his insulin therapy, resulting in a marked decrease in the amount of insulin required daily (lowering insulin aspart to 20 units/d and degludec to 7 units/d) and the improvement of glycemic control (his HbA1c level dropped from 8.5% to 7.4%). G-banding analysis demonstrated that no normal Chr13 was observed in 30 peripheral blood lymphocytes. The karyotype was a mosaic pattern (Fig. 1C-1E ). The microarray-based comparative genomic hybridization analysis (Fig. 2) showed a 4.8-Mb region of hemizygous loss in Chr13q34qter containing 40 genes ( Table 1) . The analysis showed no other structural genomic imbalances apart from the Chr13q loss.
Discussion
The common characteristics of patients with ring Chr13 include microcephaly, mental retardation, growth retardation, dysmorphic facies, and autism [5] . The clinical characteristics and severity depend on the size of the deleted region, likely due to differences in the number of absent genes. The patient in this report with ring Chr13 has relatively mild symptoms compared with previous reports of Chr13q34 deletions [1, 2] , suggesting a mild decrease of gene dosage, because of this patient's mosaicism. It is noteworthy that diabetes mellitus developed in this patient; this was described in only one case previously [6] , to our knowledge. In that report, diabetes mellitus was noted to have developed when that patient was 12 years old; treatment was insulin [6] . No other information was available in the report. Therefore, the case reported here provides new information about diabetes mellitus in Chr13q 2 syndrome.
To identify the genes that are potentially affected by the deletion of Chr13q34qter that lead to abnormal glucose homeostasis due to gene dosage alteration, we retrieved information from an online database (https://genome-asia.ucsc.edu/index.html). Among the 40 genes located in the hemizygous loss region of Chr13q34qter, insulin receptor substrate 2 (IRS2) may be a causative candidate gene that explains the phenotype of diabetes mellitus in our patient. Dysfunction of IRS2 contributes to insulin resistance, as evidenced by the progressive deterioration of glucose homeostasis observed in Irs2 knockout mice [7] .
Reinstein et al. [8] reported on two families with heterozygous microdeletions of Chr13q34 in which an intellectual disability developed. Their phenotypes were mild compared with previous reports of Chr13q34 deletions [1, 2] and equal to that of our patient, except for the development of diabetes mellitus. Those patients were all older than 20 years (range, 22 to 57 years), had intellectual disabilities, and were overweight, with no additional medical illness. As shown in Fig. 2D , the region of Chr13q34 deletion in our case is different from those in previous cases [8] , leading to gene dosage defects in an additional six genes: IRS2, COL4A1, COL4A2, RAB20, CARKD, and CARS2. Because diabetes did not develop in anyone in the two families and none of them had an IRS2 defect, it is reasonable to speculate that the IRS2 defect caused diabetes mellitus in our patient. Needless to say, the other genes except for IRS2 may also contribute to the development of diabetes.
Besides diabetes mellitus, our patient's clinical picture included a prolonged prothrombin time and WPW syndrome. The prolonged prothrombin time may be caused the by defect in F7, F10, or PROZ, and similar cases have been reported [9] . The relationship between WPW syndrome and the deletion of Chr13q34 is currently unknown because no candidate genes are located in the deleted region and, to our knowledge, no other case with WPW syndrome has been reported.
Conclusion
The patient in the current report, who has ring Chr13, has an apparently unique phenotype of delayed growth, mental retardation, and the development of early-onset diabetes mellitus. Microarray analysis detected a 4.8-Mb deletion of Chr13q34 encompassing 40 genes. The region contains a candidate gene for diabetes, IRS2. These data provide important information regarding the contribution of the microdeletion, including in IRS2, to the pathogenesis of diabetes mellitus in humans. Additional studies, including the accumulation of additional case reports, are needed to clarify these findings in humans.
